Lexeo Therapeutics Inc.

06/29/2026 | Press release | Distributed by Public on 06/29/2026 15:06

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 25, 2026, Lexeo Therapeutics, Inc. (the "Company") held its virtual 2026 Annual Meeting of Stockholders (the "Annual Meeting") exclusively online via live webcast. The stockholders voted on the following proposals at the Annual Meeting:

Proposal 1. Election of Class III Directors

The Company's stockholders elected the persons listed below as Class III Directors, to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows:

FOR

WITHHELD

BROKER NON-VOTE

R. Nolan Townsend

64,731,479

895,808

9,955,777

Brenda Cooperstone, M.D.

48,792,570

16,834,717

9,955,777

Paula HJ Cholmondeley

64,652,712

974,575

9,955,777

Proposal 2. Ratification of Appointment of Independent Registered Public Accounting Firm

The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows:

FOR

AGAINST

ABSTAIN

75,497,386

55,579

30,099

For more information about the foregoing proposals, see the Proxy Statements filed with the Securities and Exchange Commission on April 30, 2026.

Lexeo Therapeutics Inc. published this content on June 29, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 29, 2026 at 21:06 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]